Ionis presents positive results from OASIS-HAE and OASISplus studies of...
Donidalorsen delivered significant and sustained reductions in HAE attacks, with high levels of disease control and improvement in quality of life measures with monthly or every two-month dosing;...
View ArticleApproval for Wainua
The post Approval for Wainua appeared first on Ionis Pharmaceuticals, Inc..
View ArticleIonis to present at TD Cowen Genetic Medicines & RNA Summit
CARLSBAD, Calif. , June 17, 2024 /PRNewswire/ — Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will participate in a fireside chat at the virtual TD Cowen Genetic Medicines...
View ArticleIonis announces expanded licensing agreement with Otsuka in Asia Pacific for...
Otsuka will be responsible for commercialization efforts for donidalorsen across both Asia Pacific and Europe Ionis plans to independently bring donidalorsen to U.S. patients, if approved CARLSBAD,...
View ArticleIonis announces olezarsen FCS New Drug Application accepted for Priority...
– Olezarsen PDUFA date set for December 19, 2024 for treatment of familial chylomicronemia syndrome – – Phase 3 enrollment completed in CORE, CORE2 and ESSENCE evaluating olezarsen for...
View ArticleIonis announces webcast to report HALOS study results for ION582 in Angelman...
Webcast scheduled for Monday, July 22 at 8:00 a.m. Eastern Time CARLSBAD, Calif. , July 8, 2024 /PRNewswire/ — Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that it will host a live...
View ArticleIonis completes enrollment in pivotal trial evaluating zilganersen in people...
Zilganersen is the first investigational medicine in clinical development for people with Alexander disease, a rare, life-threatening neurological condition CARLSBAD, Calif. , July 18, 2024...
View ArticleIonis to hold second quarter 2024 financial results webcast
Webcast scheduled for Thursday, August 1 at 11:30 a.m. Eastern Time CARLSBAD, Calif. , July 19, 2024 /PRNewswire/ — Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that it will host a live...
View ArticleIonis announces positive detailed results from the HALOS Study of ION582 in...
ION582 showed robust and consistent benefit in communication, cognition and motor function in a broad patient population evaluated with a comprehensive set of assessment tools that collect input from...
View ArticleIonis reports second quarter 2024 financial results
WAINUA TM U.S. launch progressing well; approved in Canada ; EU approval decision expected this year Olezarsen PDUFA December 19, 2024 for FCS Positive Phase 3 donidalorsen data for HAE; preparing...
View ArticleIonis announces proposed public offering of common stock
CARLSBAD, Calif. , Sept. 9, 2024 /PRNewswire/ — Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced a proposed underwritten public offering of $500.0 million of its common stock. Ionis intends...
View ArticleIonis announces pricing of $500.3 million public offering
CARLSBAD, Calif. , Sept. 9, 2024 /PRNewswire/ — Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced the pricing of an underwritten public offering of 11,500,000 shares of its common stock. The...
View ArticleZilganersen granted U.S. FDA Fast Track designation for people living with...
Zilganersen is the first investigational medicine in clinical development for adults and children living with Alexander disease, an ultra-rare neurological condition CARLSBAD, Calif. , Oct. 1, 2024...
View ArticleNew positive donidalorsen data to be presented at 2024 American College of...
– Data continue to demonstrate donidalorsen potential to deliver significant and sustained reductions in HAE attacks up to three years with monthly or every two-month dosing CARLSBAD, Calif. , Oct....
View Article